Irina B. Lysenko

ORCID: 0000-0003-4457-3815
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Cancer Immunotherapy and Biomarkers
  • Viral-associated cancers and disorders
  • Monoclonal and Polyclonal Antibodies Research
  • Multiple Myeloma Research and Treatments
  • CNS Lymphoma Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Sarcoma Diagnosis and Treatment
  • Hematological disorders and diagnostics
  • Cancer Cells and Metastasis
  • Silymarin and Mushroom Poisoning
  • Parvovirus B19 Infection Studies
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • Lung Cancer Treatments and Mutations
  • Cutaneous lymphoproliferative disorders research
  • Inflammatory Biomarkers in Disease Prognosis
  • Neuroblastoma Research and Treatments
  • Chemical Reactions and Isotopes
  • Acute Lymphoblastic Leukemia research
  • Glycosylation and Glycoproteins Research
  • Immunotherapy and Immune Responses
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Neutropenia and Cancer Infections

Ministry of Health of the Russian Federation
2020-2024

Rostov Research Institute of Oncology
2014-2022

Tadeusz Robak Jie Jin Halyna Pylypenko Gregor Verhoef Noppadol Siritanaratkul and 95 more Johannes Drach Markus Raderer Jiřı́ Mayer Juliana Pereira Gayane Tumyan Rumiko Okamoto Susumu Nakahara Peter Hu Carlos Appiani Sepideh Nemat Franco Cavalli Achiel Van Hoof Adriana Sheliga Adriana Teixeira Akihiro Tomita Albert Oriol Rocafiguera А. Н. Суворов Alexy Kuzmin Ali Khojasteh Amel Mézlini А К Голенков André Bosly Andrew R. Belch Ann Van de Velde Árpád Illes Ashis Mukhopadhyay Balkis Meddeb Bernard De Prijck Bernardo Garichochea Bülent Ündar Caballero Gabarrón Carmen Cao Cármino Antônio De Souza Charles M. Farber Cheol Won Suh C Burcoveanu C. Cebotaru Cristina-Ligia Truica Dai Maruyama David Belada Dina Ben Yehuda Dmitry Udovitsa Dolores Enrica Morra E. Späth‐Schwalbe Eva González‐Barca Evgenii A. Osmanov Francisco Capote Fritz Offner Gálvez Cárdenas Georg Heß Georgii Manikhas Govind Babu Grigoriy Rekhtman Guiseppe Rossi Herlander Marques Horia Bumbea Huaqing Wang Huiqiang Huang Ilseung Choi Irina Bulavina Irina B. Lysenko Irit Avivi Iryna Kryachok Jan Maciej Zaucha Jan Novák Joaquín Díaz Judit Demeter Julia Alexeeva Jun Zhu Kateryna Vilchevskaya Kenichi Ishizawa Kenny Mauricio Kensei Tobinai Kiyoshi Ando Kudrat Abdulkadryrov Lee‐Yung Shih Lyudmila Kuzina Mahmut Gümüş Maike de Wit Marcelo Capra Margarida Marques Marina Golubeva Mario Ojeda‐Uribe Maryna Kyselyova Masafumi Taniwaki Massimo Federico Michael Crump Michele Baccarani Michinori Ogura Miklós Egyed M. Udvardy Mitsutoshi Kurosawa Naokuni Uike Nuriet K. Khuageva

10.1016/s1470-2045(18)30685-5 article EN The Lancet Oncology 2018-10-19

Aim. To evaluate the effectiveness and safety of Extimia® BIOCAD (international non-proprietary name: empegfilgrastim) to reduce incidence duration neutropenia, febrile neutropenia (FN) infections associated with FN in patients lymphoproliferative diseases receiving myelosuppressive therapy.
 Materials methods. The paper presents results a multicenter retrospective-and-prospective observational post-marketing study cytotoxic therapy. Initially, was defined as...

10.26442/18151434.2023.4.202539 article EN Journal of Modern Oncology 2024-02-21

Peripheral blood hematopoietic stem cell (HSC) transplantation is a well-established procedure for the treatment of hematological, cancer and autoimmune diseases. In patients, HSC allows use high-dose cytotoxic drugs in combination with radiation therapy during treatment, which provides pronounced antitumor effect. The hematological toxicity such eliminated by sequential introduction cells, contribute to hematopoiesis restoration. Before transplantation, peripheral HSCs are subjected...

10.15829/1728-8800-2023-3691 article EN cc-by CARDIOVASCULAR THERAPY AND PREVENTION 2023-12-10

Purpose : to study the level of LAG-3 expression on B-lymphocytes and feasibility using it as a marker for predicting response therapy in patients with chronic lymphocytic leukemia (CLL). Material Methods . The included 40 newly diagnosed CLL. All were divided into two groups: group I: Binet stage A, who did not receive II: C, received immunochemotherapy RB FCR regimes. According treatment regimen hematological therapy, 4 subgroups distinguished: IIA-RB, IIA-FCR, IIB-RB, IIB-FCR. control...

10.21294/1814-4861-2023-22-2-34-42 article EN cc-by Siberian Journal of Oncology 2023-04-29

The prospects of using the selective plasma exchange in treatment first identified multiple myeloma (secretory) is substantiated (MM). Twenty-four patients (16 men and 8 women) were examined with stage II−III disease. Patients divided into two groups: main group (n = 13) inclusion therapy included a control 11) — treated according to standard protocol. received specific VCD scheme. concentrations paraprotein, free light chains Ig (FLC), glomerular filtration rate (GFR), blood toxicity...

10.21320/1818-474x-2019-2-98-104 article EN cc-by-nc-sa Annals of critical care 2019-03-26

Aim. To create a collection of samples blood components patients with multiple myeloma for potential fundamental and applied biomedical research. Material methods . The material was collected according to the developed algorithm, including clinical information, biological material, sample preparation, quality control storage in biobank National Medical Research Center Oncology. Results. As August 2021, cryostorage Oncology contains 175 serum, plasma mononuclear cell fraction myeloma. Samples...

10.15829/1728-8800-2021-3043 article EN cc-by CARDIOVASCULAR THERAPY AND PREVENTION 2022-01-09

Aim. To assess effectiveness and safety of Extimia BIOCAD (INN: empegfilgrastim) used to decrease the rate duration neutropenia, febrile neutropenia infections that manifest in patients with lymphoproliferative diseases who receive myelosuppressive therapy.
 Materials methods. The paper presents results second interim analysis multicenter retrospective-and-prospective observational post-marketing study cytotoxic therapy. stage describes patient characteristics, therapy 221...

10.26442/18151434.2022.1.201493 article EN Journal of Modern Oncology 2022-04-30

e23579 Background: Retroperitoneal tumors are rare heterogeneous malignant tumors. Due to their poor response chemoradiotherapy, surgery is the main treatment option. Currently, there little data on outcomes in patients who underwent en block resection of retroperitoneal and major vessels. Our purpose was analyze surgical oncological results with blood vessel involvement. Methods: 27 received for 2015-2019. Results: The mean tumor diameter 17 cm (11-39 cm). most frequent histological types...

10.1200/jco.2020.38.15_suppl.e23579 article EN Journal of Clinical Oncology 2020-05-20

Purpose of the study . To evaluate diagnostic significance accelerated and affordable verification a bloodstream infection pathogen using biomarkers: procalcitonin Platelia ™ Candida Ag Plus mannan antigen. Patients methods 349 cancer patients with febrile fever were examined from 6 medical oncological hospitals in Southern Federal District Russian Federation during 2019. aged 1 to 85 years hospitalized intensive care, pediatric oncology hematology departments. Patient informed consent for...

10.37748/2687-0533-2020-1-4-2 article EN cc-by South Russian Journal of Cancer 2020-11-27

Background. Recently, studies have been conducted all over the world to study role of immune checkpoints in pathogenesis chronic lymphocytic leukemia (CLL) and possibility their use as prognostic markers. Of greatest interest are PD-1 (programmed cell death-1) LAG-3 protein (lymphocyte-activation gene 3). Aim. To features (CD279) (CD223) expression on blood B-cells CLL patients early markers for predicting hematological response therapy. Materials methods. The 30 with stage C according Binet...

10.17650/1818-8346-2023-18-4-156-162 article EN cc-by Oncohematology 2023-12-08

Introduction . Multiple myeloma (MM) accounts for 1% of all cancers and about 10% hematological malignancies. Although there are many types current therapeutic approaches, MM still remains an incurable disease, which points to the need improvement management patients with this disease in real-world clinical settings. Aim To analyze actual practice treating Russian multiple (MM). Materials methods A multicenter observational retrospective study was conducted. The final analysis included data...

10.21518/ms2023-431 article EN cc-by-nc-nd Meditsinskiy sovet = Medical Council 2024-01-19

Background. High-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT) is currently regarded as a standard treatment for patients relapsed/refractory classical Hodgkin lymphoma (cHL). The efficacy of correlates the depth antitumor response achieved on pre-transplantation chemotherapy. A combination PD-1 inhibitors new forward-looking approach ensuring higher rate complete responses prior to auto-HSCT well better outcomes in general.
 Aim. To assess...

10.21320/2500-2139-2024-17-1-1-10 article EN cc-by-nc-sa Clinical oncohematology 2024-02-19

Aim. To study the glomerular filtration rate (GFR) dynamics calculated by creatinine and cystatin C during induction immunochemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma order to objectify method for estimation. Materials methods. The open longitudinal included 39 who received specialized treatment at Oncohematology Department of National Medical Research Centre Oncology (Rostov-on-Don) 2021. Patients according R-CHOP regimen (rituximab, doxorubicin,...

10.17650/1818-8346-2024-19-2-67-74 article EN cc-by Oncohematology 2024-04-03

AIM. To analyze the bone marrow lymphocyte subpopulation based on targeted assessment of PD-1, PD-L1, and LAG-3 marker expression in chronic lymphocytic leukemia (CLL) patients with different responses to chemotherapy. MATERIALS & METHODS. In 33 CLL patients, antigen В-, Т-, NK-cells (BM) was analyzed by flow cytofluorometry prior treatment after 6 cycles chemotherapy rituximab. Patients were aged 58–68 years (median 64 years); there 14 women 19 men. Hematologic response assessed...

10.21320/2500-2139-2024-17-4-376-383 article EN Clinical oncohematology 2024-10-01

With a frequency of 2.2 cases per 100,000 population in Russia, Hodgkin's lymphoma (HL) is one the most common malignant neoplasms young people. In connection with predominant spread HL among people, issue effective treatment various forms remains relevant. Currently, 70-90 % patients who have received standard chemotherapy or chemoradiotherapy long period remission. However, 10 progressive course, can`t achieve response, and 30 subsequently recur. The approach treating recurrent and/or...

10.37748/2686-9039-2021-2-2-4 article EN cc-by South Russian Journal of Cancer 2021-06-20

e20027 Background: Our aim was a comparative analysis of the intensity lipid peroxidation, activity antioxidant enzymes, functional state albumin, and indices endogenous intoxication in blood patients with multiple myeloma (MM) during multi-course chemotherapy. Methods: Plasma content malondialdehyde (MDA), superoxide dismutase (SOD) catalase erythrocytes, total effective concentrations albumin (TCA ECA), level medium mass molecules (MMM), toxicity index (TI = TCA / ECA – 1) factor (IF...

10.1200/jco.2018.36.15_suppl.e20027 article EN Journal of Clinical Oncology 2018-05-20

Aim . To study the efficacy and safety of combined immunochemotherapy according to DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation. Materials methods The consisted 2 phases: 1 st - immunotherapy (2 injections as monotherapy at a dose 240 mg/day 14 days interval); nd (14 after administration nivolumab): 480 on day combination chemotherapy protocol, 4 cycles total. effectiveness therapy was...

10.17650/1818-8346-2022-17-3-40-47 article EN cc-by Oncohematology 2022-07-19

Purpose of the study . To expression immunophenotypic marker molecules on B-lymphocytes patients with chronic lymphocytic leukemia at stages immunochemotherapy while monitoring minimal residual disease. Patients and methods 20 CLL were examined, who in period 2019–2022 underwent 6 courses (ICT) RB/FCR mode National Medical Research Centre for Oncology, Rostov-on-Don. Before, after 3, ICT, bone marrow immunophenotyping was performed by flow cytometry. The data is evaluated Statistica 13.0....

10.37748/2686-9039-2022-3-4-5 article EN cc-by South Russian Journal of Cancer 2022-11-21

ПРОТИВООПУХОЛЕВАЯ АКТИВНОСТЬ АЛКАЛОИДОВ ТРОПОЛОНОВОГО РЯДА IN VITRO И VIVOМаксимов А.Ю. 1 , Лукбанова Е.А. Саяпин Ю.А. 3 Гусаков 2 Гончарова А

10.17513/spno.29722 article RU Современные проблемы науки и образования (Modern Problems of Science and Education) 2020-01-01

e14018 Background: Apoptosis is important process in the tumor cell death and poorly studied L pts. Methods: An analysis ofapoptosis was made with an annexin test vitro bone marrow culture. The effect of pentoxyphyline low concentrations on cells 40 pts newly diagnosed relapses. Bone samples (2 ml) were placed into test-tubes heparinized medium treated diluted isotonic sodium chloride solution a concentration 10-6/ml. aspirate equivalent volume used as control. carried out dependence mts to...

10.1200/jco.2014.32.15_suppl.e14018 article EN Journal of Clinical Oncology 2014-05-20

Parameters of ploidity and kinetics cell cycle in bone marrow samples lymphoma patients were studied by flow cytometry. These parameters compared to the prognostic criteria: disease stage, levels lactate dehydrogenase, sed rate test, B-symptoms, Bcl-2, Ki-67 etc. Analysis results shows, that lesions primary tumors are characterized a statistically significant increase Bcl2-expressing cells percentage G0-1 stage cycle, as well decrease G2М S stages proliferative pool S+G2M, (G2M+S) /...

10.18027/2224-5057-2018-8-2-5-11 article EN cc-by Malignant tumours 2018-07-11

Aim. To study the prevalence of carriage polymorphic allele variants genes blood coagulation factors in oncological patients.
 Materials and Methods. 213 Patients with morphologically confirmed diseases were examined. Samples genomic DNA peripheral patients Using polymerase chain reaction (PCR), sites hemostatic system studied real time: F2 (G20210А, rs1799963), F5 (G1691A, rs6025), F7 (G10976A, rs6046), F13 (G226A, rs5985), FGB G(-455)A (rs1800790), ITGA2-2 (C807T, rs1126643), ITGB3-b...

10.23888/pavlovj202028144-56 article EN I P Pavlov Russian Medical Biological Herald 2020-04-09
Coming Soon ...